Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 2, 2012, Pages 258-262

  Yanik, Elizabeth L ^a   Napravnik, Sonia ^a,b   Hurt, Christopher B ^b   Dennis, Ann ^b   Quinlivan, E Byrd ^b   Sebastian, Joe ^c   Kuruc, Joann D ^b   Eron, Joseph J ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

acute HIV infection; antiretroviral resistance; HIV 1; transmitted drug resistance

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TRANSMITTED ANTIRETROVIRAL RESISTANCE; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTI-RETROVIRAL AGENTS; CHRONIC DISEASE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RNA, VIRAL;

EID: 84866987811     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182618f05     Document Type: Article

References (24)

1. CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006;20:21-28.
2. Taniguchi T, Nurutdinova D, Grubb JR, et al. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28:259-264.
3. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-371.
4. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2011. Available at: http://aidsinfo.nih.gov/contentfile-s/ AdultandAdolescentGL.pdf. Accessed September 15, 2011.
5. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200: 1503-1508.
6. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24:1203-1212.
7. Peterman TA, Lindsey CA, Selik RM. This place is killing me: a comparison of counties where the incidence rates of AIDS increased the most and the least. J Infect Dis. 2005;191(suppl 1):S123-S126.
8. Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina, 1998 to 2007. Antivir Ther. 2009;14:673-678.
9. Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One. 2010;5:e15510.
10. Centers for Disease Control and Prevention (CDC). Divisions of HIV/AIDS Prevention. Expanded Testing Program Overview. Available at: http://www.cdc.gov/hiv/resources/factsheets/HIV-ETP.htm. Accessed August 22, 2011.
11. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for HIV care in the United States and Canada. Clin Infect Dis. 2010;50:1512-1520.
12. Napravnik S, Eron JJ, McKaig RG, et al. Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care. 2006;18(suppl 1):S45-S50.
13. Pilcher CD, Fiscus SA, Nquyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352: 1873-1883.
14. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 Update. PLoS One. 2009;4:e4724.
15. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
16. Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther. 2011;16:137-140.
17. Poon AF, Aldous JL, Mathews WC, et al. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One. 2011;6:e21189.
18. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011;203:1174-1181.
19. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol. 2008;82:5510-5518.
20. Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis. 2007;196:356-360.
21. Hue S, Gifford RJ, Dunn D, et al. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol. 2009;83:2645-2654.
22. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure. JAMA. 2011;305:1327-1335.
23. Leaity S, Sherr L, Wells H, et al. Repeat HIV testing: high-risk behaviour or risk reduction strategy? AIDS. 2000;14:547-552.
24. Bartmeyer B, Kuecherer C, Houareau C, et al. Prevalence of transmitted drug resistance and impact of transmitted drug resistance on treatment success in the German HIV-1 seroconverter cohort. PLoS One. 2010;5:e12718.